Irinotecan Versus Only Best Supportive Care for Gastric Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The median survival at progression after first-line chemotherapy for metastatic gastric
cancer is about 2.5 months. There are no data which a possible benefit of second line
therapy. for this reason a trial which investigates a possible benefit or chemotherapy
compared to best supportive care as second line treatment is urgently necessary.
Irinotecan shows response rates of 20% in the first line therapy with high rates od disease
stabilization. There are few trials investigating irinotecan in the second line setting.
Response rates of 20% are reported in tis setting. Irinotecan is supplied without costs from
the company Pfizer.